OMERS ADMINISTRATION Corp Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

OMERS ADMINISTRATION Corp boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,252 shares of the biopharmaceutical company's stock after purchasing an additional 891 shares during the period. OMERS ADMINISTRATION Corp's holdings in Alnylam Pharmaceuticals were worth $1,236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $61,160,000. Strategic Financial Concepts LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $41,529,000. Truist Financial Corp raised its stake in shares of Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after acquiring an additional 2,539 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after acquiring an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock valued at $4,687,000 after acquiring an additional 2,285 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ALNY. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. HC Wainwright reiterated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Down 0.1%

Alnylam Pharmaceuticals stock traded down $0.18 during midday trading on Tuesday, hitting $291.68. 627,258 shares of the stock were exchanged, compared to its average volume of 910,836. Alnylam Pharmaceuticals, Inc. has a 52-week low of $146.79 and a 52-week high of $304.39. The stock has a market capitalization of $38.03 billion, a price-to-earnings ratio of -134.41 and a beta of 0.17. The business's 50-day moving average price is $254.72 and its 200-day moving average price is $253.61. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The business's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.16) EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.